Serum sphingosine negatively correlates with albumin predicting the risk of hepatocellular carcinoma
Language English Country Czech Republic Media print-electronic
Document type Journal Article
PubMed
31074463
DOI
10.5507/bp.2019.015
Knihovny.cz E-resources
- Keywords
- HCC, albumin, serum sphingolipid,
- MeSH
- alpha-Fetoproteins metabolism MeSH
- Carcinoma, Hepatocellular blood complications diagnosis pathology MeSH
- Liver Cirrhosis blood complications MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasms, Multiple Primary blood complications diagnosis MeSH
- Liver Neoplasms blood complications diagnosis pathology MeSH
- Risk MeSH
- ROC Curve MeSH
- Serum Albumin metabolism MeSH
- Sphingosine blood MeSH
- Case-Control Studies MeSH
- Tumor Burden MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- alpha-Fetoproteins MeSH
- Serum Albumin MeSH
- Sphingosine MeSH
BACKGROUND: The roles of sphingosine in various cancers have not been fully investigated. Our aim was to identify the relationship between serum sphingosine and the risk of hepatocellular carcinoma (HCC). METHODS: Serum sphingosine in 34 normal people and 73 HCC patients were reviewed retrospectively. Receiver operating characteristic curve analysis was performed to determine the cut-off values of sphingosine in the serum. Chi-square test, t test and regression analysis were used to test the association between serum sphingosine and individual clinicopathologic parameters. RESULTS: Serum sphingosine was higher in HCC patients (155.91±331.5 ng/mL) with normal persons as the control (30.92±29.4 ng/mL). The sphingosine threshold according to ROC curve was set at 22.5 ng/mL with a sensitivity of 74%, and a specificity of 55.9%. Meanwhile, sphingosine in HCC patients with abnormal albumin was significantly higher than that in patients with normal albumin (t=2.452, P=0.019). When HCC patients were divided into two groups serum sphingosine was negatively associated with albumin in HCC patients (χ2=4.469, P=0.035). Moreover, the logistic regression analysis showed that large tumor size (P=0.018, OR=0.13) and a low albumin (P=0.005, OR=8.856) were two independent risk factors for serum sphingosine upregulation. High AFP coupled with high serum sphingosine, high sphingosine and high AFP respectively were found in 91.2%, 75.4%, 73% of the HCC patients. CONCLUSIONS: These results suggest that serum sphingosine could be treated as a marker for the risk of HCC. AFP and sphingosine in the serum could be used together for HCC diagnosis.
References provided by Crossref.org
